NT5E and non-small cell lung carcinoma: As the prognostic value of expression of CD73 in NSCLC remains debatable [55], there is an urgent need to standardise methodologies for CD73 IHC evaluation by using larger, well-characterised patient cohorts to clarify the potential of CD73 as a predictive or prognostic marker, which could provide valuable insights into its suitability in guiding anti-CD73 therapeutic strategies.